Related Experiment Video
Updated: Feb 1, 2026

Reducing State Anxiety Using Working Memory Maintenance
Published on: July 19, 2017
NOP Ligands for the Treatment of Anxiety and Mood Disorders
Elaine C Gavioli1, Victor A D Holanda2, Chiara Ruzza3
1Behavioral Pharmacology Laboratory, Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal, Brazil. egavioli@hotmail.com.
Abstract:
Many studies point toward the nociceptin/orphanin FQ (N/OFQ) and the N/OFQ peptide receptor (NOP) as targets for the development of innovative drugs for treating anxiety- and mood-related disorders. Evidence supports the view that the activation of NOP receptors with agonists elicits anxiolytic-like effects, while its blockade with NOP antagonists promotes antidepressant-like actions in rodents. Genetic studies showed that NOP receptor knockout mice display an antidepressant-like phenotype, and NOP antagonists are inactive in these animals. In contrast, the genetic blockade of NOP receptor signaling generally displays an increase of anxiety states in the elevated plus-maze test. In this chapter we summarized the most relevant findings of NOP receptor ligands in the modulation of anxiety and mood disorders, and the putative mechanisms of action are discussed.
Insights
The nociceptin/orphanin FQ peptide receptor (NOP) and its ligands show promise for treating anxiety and mood disorders. NOP agonists reduce anxiety, while antagonists show antidepressant effects in preclinical models.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- The nociceptin/orphanin FQ (N/OFQ) peptide and its receptor (NOP) are implicated in regulating mood and anxiety.
- Preclinical evidence suggests NOP receptor activity influences anxiety- and depression-like behaviors.
Purpose of the Study:
- To summarize key findings on NOP receptor ligands in modulating anxiety and mood disorders.
- To discuss the potential mechanisms of action for NOP receptor modulation in these conditions.
Main Methods:
- Review of preclinical studies investigating NOP receptor agonists and antagonists.
- Analysis of genetic studies involving NOP receptor knockout mice.
- Behavioral assessments in rodent models of anxiety and depression.
Main Results:
- NOP receptor activation by agonists produces anxiolytic-like effects in rodents.
- NOP receptor blockade by antagonists promotes antidepressant-like effects.
- Genetic deletion of NOP receptors results in an antidepressant-like phenotype, with NOP antagonists showing no effect.
Conclusions:
- NOP receptor signaling plays a significant role in the neurobiology of anxiety and mood disorders.
- Targeting the NOP receptor with specific ligands offers a potential therapeutic strategy for these conditions.
- Further research into NOP receptor mechanisms is warranted for drug development.
Related Concept Videos
Social Anxiety Disorder
Generalized Anxiety Disorder
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
Anxiety: Overview
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.

